4 January 2021 in Journal of Clinical Pharmacy and Therapeutics
1 January 2022 in The Journal of Medical Investigation
Background : We herein report the use of independent lung ventilation (ILV) for managing acute allograft rejection after single-lung transplantation (SLT) for end-stage emphysema. Case presentation : A 54-year-old woman was transferred to our hospital with severe hypoxemia and respiratory distress due to unilateral lung disease with diffuse alveolar damage in the right donor lung associated with acute allograft rejection and with hyperinflation of the left native lung due to emphysema. She was unresponsive to immunosuppressive medications and conventional ventilation strategies, so different ventilator settings for each lung were required. A double-lumen endotracheal tube (DLT) was inserted, and ILV was initiated. The right lung was ventilated with high positive end-expiratory pressure (PEEP), intended for lung recruitment, and the left lung was ventilated with lung protective strategies using a low tidal volume and low levels of PEEP to avoid hyperinflation. Two days later, her lung function was dramatically improved, and the DLT was replaced with a single-lumen endotracheal tube. Gas exchange was maintained, and she was successfully weaned from mechanical ventilation on intensive-care unit day 15. Conclusions : ILV appears to be effective and safe for managing acute allograft rejection after SLT for emphysema. J. Med. Invest. 69 : 323-327, August, 2022
12 August 2026 in Hospital Pharmacy
Introduction: Accurate model-based prediction of vancomycin concentration is essential for therapeutic drug monitoring (TDM); however, the practical criteria for selecting population pharmacokinetic (PopPK) models remain unclear. We compared the predictive performances of the Japanese Oda and Yamamoto PopPK models. Methods: This single-center retrospective study included adults aged ≥18 years who underwent vancomycin TDM between January 2023 and December 2024. Vancomycin concentrations were predicted using both models. Predictive performance was evaluated by absolute error (AE) and ΔAE, defined as AE for the Oda model minus AE for the Yamamoto model. Decision tree analysis was used to assess patient characteristics associated with differences in prediction error between the 2 models. Results: Of the 396 patients, 296 were analyzed; the median age was 80 years. The mean AE values for the Oda and Yamamoto models were 3.61 ± 3.01 and 3.78 ± 2.89 µg/mL, respectively (ΔAE, −0.172 µg/mL). Creatinine clearance (CCr), body weight (BW), age, and serum albumin (Alb) were selected as splitting variables in the decision tree analysis, and most terminal nodes displayed lower AE in the Oda model. In limited subgroups, including patients with very high CCr, lower BW, and older age, the Yamamoto model showed a lower AE. Using rounded-up serum creatinine (SCr), the mean AE was 3.63 ± 2.95 and 3.96 ± 2.99 µg/mL, respectively, for the Oda and Yamamoto models (ΔAE, −0.334 µg/mL). Rounding up a low SCr level did not improve the overall predictive performance. Conclusion: The Oda model showed a slightly lower prediction error than the Yamamoto model and may be a reasonable first-choice PopPK model for vancomycin TDM in elderly Japanese patients. Routine rounding at low SCr levels is not supported.